Company Overview
About eMed
eMed is a GLP-1 and metabolic health benefits platform built specifically for employer-sponsored health plans, the fastest-growing category in US workplace benefits. The company raised $200 million in Series A financing in March 2026 at a $2 billion+ valuation led by AON Consulting, with backing from Linda Yaccarino (former Twitter/X CEO, now eMed CEO) and Tom Brady. Claiming 91%+ medication adherence rates, eMed positions itself as the most effective GLP-1 benefits program available to employers.
Business Model & Competitive Advantage
The platform's capitated pricing model shifts financial risk from employers to eMed — charging a fixed fee per member regardless of how many GLP-1 prescriptions are written — which makes total cost predictable for HR and benefits teams wrestling with runaway drug spend. GLP-1 medications (Ozempic, Wegovy) have become the most requested workplace health benefit in the US, and their list prices create budget pressure that employers urgently need managed.
Competitive Landscape 2025–2026
eMed combines clinical oversight (prescribers, pharmacists, registered dietitians) with behavioral coaching and medication management to improve outcomes and reduce GLP-1 discontinuation, which runs 50-70% in typical commercial populations. The company's approach is to treat GLP-1 therapy as a managed clinical program rather than a pharmacy benefit, driving the adherence rates it claims as a differentiator.
Open Positions
Reddit Discussions
Key Differentiators
Strong Challenger
eMed is an established challenger with significant market presence and competitive offerings in Digital Health.
Growth Stage
eMed has achieved $200M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Honda
Honda Motor Co., Ltd. is a Japanese multinational mobility conglomerate founded in 1948 by Soichiro Honda and Takeo Fujisawa in Hamamatsu, Japan. Starting as a motorcycle manufacturer, Honda expanded
Hyundai
Hyundai Motor Company was founded in 1967 in Seoul, South Korea, by Chung Ju-yung and has grown into one of the world's largest automotive manufacturers, ranking third globally by vehicle sales. From
Benchling
Benchling is a cloud-based research and development platform purpose-built for the life sciences industry, founded in 2012 by Sajith Wickramasekara and Ashu Singhal as a Y Combinator alumnus. The comp
Tesla
Tesla is an electric vehicle and clean energy company founded in 2003 by Martin Eberhard and Marc Tarpenning in San Carlos, California, and subsequently co-founded and led by Elon Musk, who joined as
Compare eMed with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from eMed? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim eMed Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention eMed vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →